Your browser doesn't support javascript.
loading
Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer.
Ishikawa, Takashi; Akazawa, Kouhei; Hasegawa, Yoshie; Tanino, Hirokazu; Horiguchi, Jun; Miura, Daishu; Hayashi, Mitsuhiro; Kohno, Norio.
Afiliação
  • Ishikawa T; Department of Breast Surgery and Oncology, Tokyo Medical University, Tokyo, Japan. Electronic address: tishik55@gmail.com.
  • Akazawa K; Department of Medical Informatics, Niigata University Medical and Dental Hospital, Niigata, Japan.
  • Hasegawa Y; Department of Breast Surgery, Hirosaki Municipal Hospital, Hirosaki, Japan.
  • Tanino H; Department of Breast and Thyroid Surgery, Kitasato University Hospital, Sagamihara, Japan.
  • Horiguchi J; Department of Breast and Endocrine Surgery, Gunma University Hospital, Maebashi, Japan.
  • Miura D; Department of Breast and Endocrine Surgery, Toranomon Hospital, Tokyo, Japan.
  • Hayashi M; Department of Breast Oncology, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Kohno N; Department of Breast Oncology, Kobe Kaisei Hospital, Kobe, Japan.
J Surg Res ; 220: 46-51, 2017 12.
Article em En | MEDLINE | ID: mdl-29180210

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Neoadjuvante / Difosfonatos / Imidazóis Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Terapia Neoadjuvante / Difosfonatos / Imidazóis Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article